JP2003144095A - Skin care preparation - Google Patents
Skin care preparationInfo
- Publication number
- JP2003144095A JP2003144095A JP2001342660A JP2001342660A JP2003144095A JP 2003144095 A JP2003144095 A JP 2003144095A JP 2001342660 A JP2001342660 A JP 2001342660A JP 2001342660 A JP2001342660 A JP 2001342660A JP 2003144095 A JP2003144095 A JP 2003144095A
- Authority
- JP
- Japan
- Prior art keywords
- fraction
- milk
- skin
- basic
- basic protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 32
- 235000013336 milk Nutrition 0.000 claims abstract description 25
- 239000008267 milk Substances 0.000 claims abstract description 25
- 210000004080 milk Anatomy 0.000 claims abstract description 25
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 108091005804 Peptidases Proteins 0.000 claims abstract description 9
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 108010019160 Pancreatin Proteins 0.000 claims abstract description 5
- 229940055695 pancreatin Drugs 0.000 claims abstract description 5
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 4
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 4
- 229940111202 pepsin Drugs 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 102000035195 Peptidases Human genes 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003729 cation exchange resin Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000000593 degrading effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 108090000317 Chymotrypsin Proteins 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 229960002376 chymotrypsin Drugs 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims 1
- 229960001322 trypsin Drugs 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 abstract description 15
- 108010035532 Collagen Proteins 0.000 abstract description 15
- 229920001436 collagen Polymers 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 230000037303 wrinkles Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 238000005194 fractionation Methods 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 35
- 238000000034 method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000037319 collagen production Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 239000006210 lotion Substances 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- -1 ester compound Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000909 electrodialysis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、皮膚の荒れ、シ
ワ、弾性低下等を防止するのに有用な美肌剤、美肌用飲
食品及び化粧料に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a skin beautifying agent, a skin beautifying food and drink, and a cosmetic which are useful for preventing rough skin, wrinkles, elasticity deterioration and the like.
【0002】[0002]
【従来の技術】近年、皮膚の老化に関する研究が進めら
れ、皮膚老化の原因としてマクロ的には、加齢による新
陳代謝の減衰によるもののほかに、太陽光(紫外線)、乾
燥、酸化等の作用が複雑に関与していることが確認され
てきた。これらの因子による作用によって、真皮の最も
主要なマトリックス成分であるコラーゲン繊維が著名に
減少していることが明らかとなってきた。コラーゲン繊
維によって保たれていた皮膚のハリや、弾力性といった
張力保持機構が紫外線等の作用によって、破壊される
と、皮膚はシワやたるみを増し、老化した状態になる。
また、コラーゲンはその分子中に水分を保持することが
でき、それにより、皮膚をしっとりとした状態に保つに
も役立っているから、外的因子により、コラーゲンが破
壊されると肌は、乾燥し、荒れた状態になる。以上のこ
とから、真皮層の重要な成分の一つであるコラーゲンの
生合成を促進させることにより、皮膚の老化を防止で
き、しかも安全性の点でも問題のない美肌剤が望まれて
いた。2. Description of the Related Art In recent years, research on skin aging has been advanced, and in terms of macroscopic causes of skin aging, in addition to the decay of metabolism due to aging, the effects of sunlight (ultraviolet rays), drying, oxidation, etc. It has been confirmed that they are involved in a complicated way. It has become clear that collagen fibers, which are the most major matrix component of the dermis, are prominently reduced by the action of these factors. When the tension and tension retention mechanism such as elasticity held by collagen fibers is destroyed by the action of ultraviolet rays or the like, the skin becomes wrinkled or sagging and becomes aged.
Collagen can also retain water in its molecule, which helps to keep the skin moist, so when external factors destroy the collagen, the skin becomes dry. , Will be in a rough state. From the above, there has been a demand for a skin beautifying agent which can prevent the aging of the skin by promoting the biosynthesis of collagen, which is one of the important components of the dermis layer, and has no problem in safety.
【0003】[0003]
【発明が解決しようとする課題】本発明者らは、これら
の問題点を鑑み、広く食品素材に含まれているコラーゲ
ン産生促進作用を示す物質について、鋭意、探索を進め
ていたところ、乳由来の塩基性タンパク質画分あるいは
その塩基性タンパク質画分をペプシンやパンクレアチン
などのタンパク質分解酵素で分解して得られる塩基性ペ
プチド画分が、皮膚のコラーゲン量を増加させることが
できることを見出した。そして、この塩基性タンパク質
画分や塩基性ペプチド画分を美肌剤、美肌用飲食品及び
化粧料の有効成分として利用できることを見出し、本発
明を完成するに至った。したがって、本発明は、この皮
膚コラーゲン産生促進活性を有する乳由来の塩基性タン
パク質画分あるいは塩基性ペプチド画分を有効成分とす
る美肌剤を提供することを課題とする。また、本発明
は、これらの画分を配合した美肌用飲食品や化粧料を提
供することを課題とする。In view of these problems, the present inventors have been earnestly searching for a substance showing a collagen production promoting action which is widely contained in food materials. It was found that the basic protein fraction of or the basic peptide fraction obtained by degrading the basic protein fraction with a proteolytic enzyme such as pepsin or pancreatin can increase the amount of skin collagen. Then, they have found that this basic protein fraction or basic peptide fraction can be used as an active ingredient of a skin beautifying agent, a skin beautifying food and drink, and a cosmetic, and have completed the present invention. Therefore, an object of the present invention is to provide a skin beautifying agent containing a milk-derived basic protein fraction or basic peptide fraction having this skin collagen production promoting activity as an active ingredient. Moreover, this invention makes it a subject to provide the food / beverage products and cosmetics for beautiful skin which mix | blended these fractions.
【0004】[0004]
【課題を解決するための手段】本発明の美肌剤の特徴
は、乳由来の塩基性タンパク質画分あるいはその塩基性
タンパク質画分をタンパク質分解酵素で分解して得られ
る塩基性ペプチド画分を有効成分とすることにある。こ
の乳由来の塩基性タンパク質画分は、牛乳、人乳、山羊
乳、羊乳など哺乳類の乳から得られるものであり、ま
た、この塩基性ペプチド画分は、乳由来の塩基性タンパ
ク質画分にタンパク質分解酵素を作用させて得ることが
できるものである。Means for Solving the Problems The feature of the skin-care agent of the present invention is that a basic protein fraction derived from milk or a basic peptide fraction obtained by degrading the basic protein fraction with a proteolytic enzyme is effective. It is to make it an ingredient. The milk-derived basic protein fraction is obtained from milk of mammals such as milk, human milk, goat milk, and sheep milk, and the basic peptide fraction is milk-derived basic protein fraction. It can be obtained by reacting a proteolytic enzyme with.
【0005】この乳由来の塩基性タンパク質画分は、後
述する試験例1〜4に示したように次の性質を有してい
る。
1) ソジウムドデシルサルフェート−ポリアクリルアミ
ドゲル電気泳動(SDS-PAGE)によると分子量 3,000〜8
0,000の範囲の数種のタンパク質よりなる。
2) 95重量%以上がタンパク質であって、その他少量の
脂肪、灰分を含む。
3) タンパク質は主としてラクトフェリン及びラクトパ
ーオキシダーゼよりなる。
4) タンパク質のアミノ酸組成は、リジン、ヒスチジ
ン、アルギニン等の塩基性アミノ酸を15重量%以上含有
する。The basic protein fraction derived from milk has the following properties as shown in Test Examples 1 to 4 described later. 1) According to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the molecular weight was 3,000 ~ 8
It consists of several proteins in the range of 0,000. 2) 95% by weight or more is protein and contains a small amount of fat and ash. 3) The protein mainly consists of lactoferrin and lactoperoxidase. 4) The amino acid composition of the protein contains 15% by weight or more of basic amino acids such as lysine, histidine, and arginine.
【0006】このような塩基性タンパク質画分は、例え
ば、脱脂乳や乳清などの乳原料を陽イオン交換樹脂と接
触させて塩基性タンパク質を吸着させ、この樹脂に吸着
した塩基性タンパク質画分を0.1M〜1Mの塩濃度の溶出液
で溶出、この溶出画分を回収し、逆浸透(RO)膜や電気透
析(ED)法などにより脱塩及び濃縮し、必要に応じて乾燥
することにより得ることができる。Such a basic protein fraction is obtained by, for example, contacting a dairy raw material such as skim milk or whey with a cation exchange resin to adsorb the basic protein, and adsorbing the basic protein fraction onto the resin. Eluate with 0.1M to 1M salt concentration eluate, collect this eluate fraction, desalt and concentrate by reverse osmosis (RO) membrane or electrodialysis (ED) method, and dry if necessary. Can be obtained by
【0007】また、乳由来の塩基性タンパク質画分を得
る方法としては、乳または乳由来の原料を陽イオン交換
体に接触させて塩基性タンパク質を吸着させた後、この
陽イオン交換体に吸着した塩基性タンパク質画分を、pH
5を越え、イオン強度 0.5を越える溶出液で溶出して得
る方法(特開平5-202098号公報)、アルギン酸ゲルを用
いて得る方法(特開昭 61-246198号公報)、無機の多孔
性粒子を用いて乳清から得る方法(特開平 1-86839号公
報)、硫酸化エステル化合物を用いて乳から得る方法
(特開昭 63-255300号公報)などが知られており、本発
明では、このような方法で得られた塩基性タンパク質画
分を用いることができる。As a method for obtaining a milk-derived basic protein fraction, milk or a milk-derived raw material is brought into contact with a cation exchanger to adsorb the basic protein, and then the cation exchanger is adsorbed. PH of the basic protein fraction
Method obtained by eluting with an eluent having an ionic strength of more than 5 and an ionic strength of more than 0.5 (JP-A-5-202098), method using an alginic acid gel (JP-A-61-246198), inorganic porous particles A method for obtaining whey from whey (JP-A-1-86839), a method for obtaining a milk using a sulfated ester compound (JP-A-63-255300), and the like are known. In the present invention, The basic protein fraction obtained by such a method can be used.
【0008】また、乳由来の塩基性ペプチド画分は、塩
基性タンパク質画分と同様のアミノ酸組成を有してお
り、例えば、上記の方法で得られた乳由来の塩基性タン
パク質画分にペプシン、トリプシン、キモトリプシンな
どのタンパク質分解酵素を作用させ、さらに必要に応
じ、パンクレアチンなどのタンパク質分解酵素を作用さ
せることにより、平均分子量 4,000以下のペプチド組成
物として得ることができる。The milk-derived basic peptide fraction has the same amino acid composition as the basic protein fraction. For example, the milk-derived basic protein fraction obtained by the above-mentioned method is treated with pepsin. A peptide composition having an average molecular weight of 4,000 or less can be obtained by acting a proteolytic enzyme such as trypsin, chymotrypsin, etc. and, if necessary, a proteolytic enzyme such as pancreatin.
【0009】本発明の美肌剤は、経口投与或いは塗布
で、美肌効果を発揮する。本発明の美肌剤を経口投与す
るに際しては、有効成分の乳由来の塩基性タンパク質画
分あるいは塩基性ペプチド画分をそのままの状態で用い
ることもできるが、常法に従い、粉末剤、顆粒剤、錠
剤、カプセル剤、ドリンク剤などに製剤化して用いるこ
ともできる。さらには、これらの塩基性タンパク質画分
や塩基性ペプチド画分をそのままあるいは製剤化した
後、これを栄養剤や飲食品などに配合することも可能で
ある。また、ビタミンCなど従来からコラーゲン産生に
有効な作用をもつと考えられている成分とともに塩基性
タンパク質画分や塩基性ペプチド画分を配合すれば、い
っそうの美肌作用が期待できる。なお、乳由来の塩基性
タンパク質画分あるいは塩基性ペプチド画分は、比較的
熱に対して安定なので、乳由来の塩基性タンパク質画分
あるいは塩基性ペプチド画分を含む原料を通常行われる
ような条件で加熱殺菌することも可能である。The skin beautifying agent of the present invention exhibits a skin beautifying effect upon oral administration or application. When orally administering the skin-care agent of the present invention, the milk-derived basic protein fraction or basic peptide fraction of the active ingredient can be used as it is, but according to a conventional method, a powder, a granule, It can also be used by formulating into tablets, capsules, drinks and the like. Furthermore, it is also possible to mix these basic protein fractions and basic peptide fractions as they are or after formulating them into nutritional supplements, foods and drinks, etc. Further, by adding a basic protein fraction or a basic peptide fraction together with a component such as vitamin C, which has been considered to have an effective action on collagen production, further skin-beautifying action can be expected. Since the milk-derived basic protein fraction or the basic peptide fraction is relatively stable to heat, it is likely that a raw material containing the milk-derived basic protein fraction or the basic peptide fraction is usually used. It is also possible to perform heat sterilization under the conditions.
【0010】本発明の美肌剤を塗布するに際しては、そ
の使用目的に応じて、通常用いられる公知の成分に配合
することによって、液剤、固形剤、半固形剤等の各種剤
形に調製することが可能で、好ましい組成物として軟
膏、ゲル、クリーム、スプレー剤、貼付剤、ローショ
ン、粉末、顆粒剤、錠剤等が挙げられる。例えば、本発
明の皮膚コラーゲン合成促進剤をワセリン等の炭化水
素、ステアリルアルコール、ミリスチン酸イソプロピル
等の高級脂肪酸低級アルキルエステル、ラノリン等の動
物性油脂、グリセリン等の多価アルコール、グリセリン
脂肪酸エステル、モノステアリン酸ポリエチレングリコ
ールの界面活性剤、無機塩、蝋、樹脂、水および要すれ
ばパラオキシ安息香酸メチル、パラオキシ安息香酸ブチ
ル等の防腐剤に混合することによって、化粧品や医薬品
を製造することができる。When applying the skin beautifying agent of the present invention, it should be prepared into various dosage forms such as liquid preparations, solid preparations and semi-solid preparations by blending it with known components which are usually used depending on the purpose of use. The preferred compositions include ointments, gels, creams, sprays, patches, lotions, powders, granules, tablets and the like. For example, the skin collagen synthesis promoter of the present invention, hydrocarbons such as petrolatum, stearyl alcohol, higher fatty acid lower alkyl esters such as isopropyl myristate, animal fats and oils such as lanolin, polyhydric alcohols such as glycerin, glycerin fatty acid ester, mono Cosmetics and pharmaceuticals can be produced by mixing with polyethylene glycol stearate surfactants, inorganic salts, waxes, resins, water and, if necessary, preservatives such as methyl paraoxybenzoate and butyl paraoxybenzoate.
【0011】本発明の美肌剤の経口投与による有効量
は、年齢、治療効果及び病態などにより異なるが、ラッ
トを用いた動物実験の結果によると、皮膚コラーゲン産
生促進作用を示すためには塩基性タンパク質画分あるい
は塩基性ペプチド画分をラット体重1kg当たり20mg以上
摂取する必要があることが判った。したがって、通常、
成人一人当たり一日20mg以上の塩基性タンパク質画分あ
るいは塩基性ペプチド画分を摂取すれば効果が期待でき
るので、この必要量を確保できるよう飲食品に配合した
り、医薬として投与すれば良い。The effective dose of the skin-care agent of the present invention by oral administration varies depending on age, therapeutic effect, pathological condition, etc., but according to the results of animal experiments using rats, it is basic to show skin collagen production promoting action. It was found that the protein fraction or basic peptide fraction should be ingested in an amount of 20 mg or more per 1 kg of rat body weight. Therefore, usually
Since an effect can be expected by ingesting 20 mg or more of a basic protein fraction or a basic peptide fraction per adult per day, it may be added to foods and drinks or administered as a medicine so as to secure this required amount.
【0012】本発明の美肌剤の塗布による有効量は、剤
形により異なるが、適用する組成物全量を基準として好
ましくは、0.001%〜2重量%となるように、塩基性タン
パク質画分あるいは塩基性ペプチド画分を配合すればよ
い。ただし、入浴剤のように使用時に希釈されるもの
は、さらに配合量を増やすことができる。次に、実施例
及び試験例を示して本発明を詳細に説明する。The effective amount of the skin beautifying agent of the present invention applied varies depending on the dosage form, but is preferably 0.001% to 2% by weight based on the total amount of the composition to be applied, so that the basic protein fraction or the base is contained. The active peptide fraction may be blended. However, a compound such as a bath agent that is diluted at the time of use can be further increased in the compounding amount. Next, the present invention will be described in detail by showing Examples and Test Examples.
【0013】[0013]
【実施例1】陽イオン交換樹脂のスルホン化キトパール
(富士紡績株式会社製)400gを充填したカラム(直径5
cm×高さ30cm)を脱イオン水で十分洗浄した後、このカ
ラムに未殺菌脱脂乳40リットル(pH 6.7)を流速25ml/min
で通液した。通液後、このカラムを脱イオン水で十分洗
浄し、 0.98M塩化ナトリウムを含む 0.02M炭酸緩衝液(p
H 7.0)で樹脂に吸着した塩基性タンパク質画分を溶出し
た。そして、この溶出液を逆浸透(RO)膜により脱塩し
て、濃縮した後、凍結乾燥して粉末状の塩基性タンパク
質画分 21gを得た。Example 1 A column (diameter 5) filled with 400 g of cation exchange resin sulfonated chitopearl (manufactured by Fuji Spinning Co., Ltd.)
(cm x height 30 cm) is thoroughly washed with deionized water, and then 40 liters of unsterilized skim milk (pH 6.7) is applied to this column at a flow rate of 25 ml / min.
It was passed at. After passing through the column, thoroughly wash this column with deionized water, and then add 0.08 M sodium chloride in 0.02 M carbonate buffer (p
The basic protein fraction adsorbed on the resin was eluted with H 7.0). Then, this eluate was desalted with a reverse osmosis (RO) membrane, concentrated, and then freeze-dried to obtain 21 g of a powdery basic protein fraction.
【0014】[0014]
【試験例1】実施例1で得られた塩基性タンパク質画分
について、ソジウムドデシルサルフェート−ポリアクリ
ルアミドゲル電気泳動(SDS-PAGE)により測定したとこ
ろ、分子量は 3,000〜80,000の範囲に分布していた。[Test Example 1] The basic protein fraction obtained in Example 1 was measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the molecular weight was distributed in the range of 3,000 to 80,000. It was
【0015】[0015]
【試験例2】実施例1で得られた塩基性タンパク質画分
について、成分組成を分析した。その結果を表1に示
す。この表に示すとおり、この画分のほとんどはタンパ
ク質である。Test Example 2 The basic composition of the basic protein fraction obtained in Example 1 was analyzed. The results are shown in Table 1. As shown in this table, most of this fraction is protein.
【0016】[0016]
【表1】 [Table 1]
【0017】[0017]
【試験例3】実施例1で得られた塩基性タンパク質画分
について、6N塩酸で 110℃、24時間加水分解した後、ア
ミノ酸分析装置(L-8500型、日立製作所製) でそのア
ミノ酸組成を分析した。その結果を表2に示す。この塩
基性タンパク質画分には、アミノ酸組成中15重量%以上
の塩基性アミノ酸が含まれている。[Test Example 3] The basic protein fraction obtained in Example 1 was hydrolyzed with 6N hydrochloric acid at 110 ° C for 24 hours, and then its amino acid composition was measured with an amino acid analyzer (L-8500 type, manufactured by Hitachi, Ltd.). analyzed. The results are shown in Table 2. This basic protein fraction contains 15% by weight or more of basic amino acids in the amino acid composition.
【0018】[0018]
【表2】 [Table 2]
【0019】[0019]
【実施例2】陽イオン交換樹脂のSPトーヨーパール
(東ソー株式会社製)30kgを充填したカラム(直径 100
cm×高さ10cm)を脱イオン水で十分洗浄した後、このカ
ラムに121℃で30秒間加熱殺菌したチーズホエー3t(pH
6.2)を流速10リットル/minで通液した。通液後、このカ
ラムを脱イオン水で十分洗浄し、0.9M塩化ナトリウムを
含む0.1Mクエン酸緩衝液(pH 5.7)で樹脂に吸着した塩基
性タンパク質画分を溶出した。そして、この溶出液を電
気透析(ED)法により脱塩し、濃縮した後、凍結乾燥して
粉末状の塩基性タンパク質画分183gを得た。Example 2 A column (diameter 100) filled with 30 kg of cation exchange resin SP Toyopearl (manufactured by Tosoh Corporation)
cm x 10 cm in height) was thoroughly washed with deionized water, and this column was heat-sterilized at 121 ° C for 30 seconds.
6.2) was passed through at a flow rate of 10 l / min. After the passage, the column was thoroughly washed with deionized water, and the basic protein fraction adsorbed on the resin was eluted with 0.1 M citrate buffer (pH 5.7) containing 0.9 M sodium chloride. Then, the eluate was desalted by electrodialysis (ED), concentrated, and then freeze-dried to obtain 183 g of a powdery basic protein fraction.
【0020】[0020]
【実施例3】実施例1で得られた塩基性タンパク質画分
50gを蒸留水10リットルに溶解した後、1%パンクレア
チン(シグマ社製)を添加し、37℃で2時間反応させ
た。反応後、80℃で10分間加熱処理して酵素を失活させ
た後、塩基性ペプチド画分48.3gを得た。Example 3 Basic protein fraction obtained in Example 1
After 50 g was dissolved in 10 liters of distilled water, 1% pancreatin (manufactured by Sigma) was added and reacted at 37 ° C for 2 hours. After the reaction, the enzyme was inactivated by heating at 80 ° C. for 10 minutes to obtain 48.3 g of a basic peptide fraction.
【0021】[0021]
【試験例4】実施例1で得られた塩基性タンパク質画分
および実施例3で得られた塩基性ペプチド画分につい
て、ラットを用いた動物実験によりコラーゲン産生促進
作用を調べた。7週齢のWistar系雄ラットを、生理食塩
水投与群(A群)、実施例1で得られた塩基性タンパク質
画分をラット体重1kg当たり20mg投与する群(B群)、実
施例1で得られた塩基性タンパク質画分をラット体重1kg
当たり200mg投与する群(C群)、実施例3で得られた塩
基性ペプチド画分をラット体重1kg当たり20mg投与する
群(D群)、実施例3で得られた塩基性ペプチド画分をラ
ット体重1kg当たり200mg投与する群(E群)の5試験群
(n=6)に分け、それぞれを毎日1回ゾンデで投与して10
週間飼育した。TEST EXAMPLE 4 With respect to the basic protein fraction obtained in Example 1 and the basic peptide fraction obtained in Example 3, the collagen production promoting action was examined by animal experiments using rats. 7-week-old Wistar male rats were administered with saline (group A), the basic protein fraction obtained in Example 1 was administered at 20 mg per 1 kg of rat body weight (Group B), and in Example 1. The obtained basic protein fraction was used for rat weighing 1 kg.
200 mg per group (C group), basic peptide fraction obtained in Example 3 at 20 mg per 1 kg of rat body weight (D group), basic peptide fraction obtained in Example 3 at rat Divided into 5 test groups (n = 6) of 200 mg / kg body weight (group E), each of which was administered once daily with a sonde 10
Raised for a week.
【0022】皮膚のコラーゲン量については、真皮をNi
mniらの方法(Arch. Biochem. Biophys, 292頁, 1967年
参照)に準じて処理した後、可溶性画分に含まれるヒド
ロキシプロリン量を測定した。ヒドロキシプロリンはコ
ラーゲンのみに含まれる特殊なアミノ酸で、コラーゲン
を構成する全アミノ酸の約10%を占めることからコラー
ゲン量の推定ができる。(浅野隆司ら Bio Industor
y, 12頁, 2001年参照)その結果を表3に示す。Regarding the amount of collagen in the skin,
After treatment according to the method of Mni et al. (see Arch. Biochem. Biophys, page 292, 1967), the amount of hydroxyproline contained in the soluble fraction was measured. Hydroxyproline is a special amino acid contained only in collagen and accounts for about 10% of all the amino acids that make up collagen, so the amount of collagen can be estimated. (Ryuji Asano et al. Bio Industor
y, p. 12, 2001) The results are shown in Table 3.
【0023】[0023]
【表3】 [Table 3]
【0024】これによると、10週間後の可溶性画分中ヒ
ドロキシプロリン量は、A群に比べ、B群、C群、D群およ
びE群で有意に高い値を示した。このことから、塩基性
タンパク質画分および塩基性ペプチド画分には皮膚コラ
ーゲン産生促進作用があることが明らかとなり、美肌剤
として有用であることが示唆された。また、この皮膚コ
ラーゲン産生促進作用は塩基性タンパク質画分または塩
基性ペプチド画分をラット体重1kg当たり最低20mg投与
した場合に認められることが明らかとなった。According to this, the amount of hydroxyproline in the soluble fraction after 10 weeks was significantly higher in group B, group C, group D and group E than in group A. From this, it was revealed that the basic protein fraction and the basic peptide fraction have an action of promoting skin collagen production, and it was suggested that they are useful as a skin beautifying agent. Further, it was revealed that this skin collagen production promoting action was observed when a basic protein fraction or a basic peptide fraction was administered at a minimum of 20 mg per 1 kg of rat body weight.
【0025】[0025]
【0026】[0026]
【実施例4】表4に示す組成の美肌用飲料を製造した。
製造した飲料の風味は良好で、常温1年間保存によって
も風味が劣化することはなく、沈殿等の問題もなかっ
た。[Example 4] A skin beautifying beverage having the composition shown in Table 4 was produced.
The produced beverage had a good flavor, the flavor did not deteriorate even after storage at room temperature for 1 year, and there was no problem such as precipitation.
【0027】[0027]
【表4】 [Table 4]
【0028】[0028]
【実施例5】表5に示す組成のドウを作成し、成形した
後、焙焼して美肌用ビスケットを製造した。Example 5 A dough having the composition shown in Table 5 was prepared, molded, and then roasted to manufacture a biscuit for beautiful skin.
【0029】[0029]
【表5】 [Table 5]
【0030】[0030]
【実施例6】表6に示す組成の美肌剤を製造した。Example 6 A skin beautifying agent having the composition shown in Table 6 was produced.
【0031】[0031]
【表6】 [Table 6]
【0032】[0032]
【試験例5】実施例1で得られた塩基性タンパク質画分
および実施例3で得られた塩基性ペプチド画分につい
て、正常ヒト線維芽細胞株〔白人女性の皮膚より採取さ
れたCCD45SK(ATCCRL 1506)〕を用いた実験によりコラ
ーゲン産生促進作用を調べた。10容量%ウシ胎児血清
(以下FBSと略記)含有MEM培地(大日本製薬社製、10‐10
1)を用いて、正常ヒト線維芽細胞株を4×104個/穴/0.4
mlとなるように24穴プレートに播種して、5%炭酸ガ
ス、飽和水蒸気下、37℃で24時間培養した後、0.6容量
%FBS含有MEM培地に置換した。そして、実施例1で得ら
れた塩基性タンパク質画分および実施例3で得られた塩
基性ペプチド画分を、各ウェルに0.1容量%となるよう
に添加して、24時間培養した後、β―アミノプロピオニ
トリルを50μg/mL、トリチウム-L-プロリンを1μCi/ml
となるように添加して、さらに24時間培養して培養液を
得た。このようにして得られた培養液より、Websterら
の方法(Analytical Biochemistry,220頁,1979年参照)
に従いコラーゲン画分を分画し、コラーゲン画分に取り
込まれた放射能を測定した。なお、対照としては、塩基
性タンパク質画分及び塩基性ペプチド画分を添加しない
で同様の試験を行った。その結果を表7に示す。Test Example 5 With respect to the basic protein fraction obtained in Example 1 and the basic peptide fraction obtained in Example 3, a normal human fibroblast cell line [CCD45SK (ATCCRL collected from the skin of a Caucasian woman was used. 1506)] was used to examine the collagen production promoting action. 10% fetal bovine serum
(Hereinafter abbreviated as FBS) containing MEM medium (Dainippon Pharmaceutical Co., Ltd., 10-10
1), normal human fibroblast cell line 4 × 10 4 cells / well / 0.4
The cells were seeded on a 24-well plate so that the amount became ml, and cultured at 37 ° C. for 24 hours under 5% carbon dioxide and saturated steam, and then replaced with a MEM medium containing 0.6% by volume FBS. Then, the basic protein fraction obtained in Example 1 and the basic peptide fraction obtained in Example 3 were added to each well at 0.1% by volume and cultured for 24 hours, followed by β -Aminopropionitrile 50 μg / mL, tritium-L-proline 1 μCi / ml
The resulting mixture was added as described above and further cultured for 24 hours to obtain a culture solution. From the culture broth thus obtained, the method of Webster et al. (Analytical Biochemistry, page 220, 1979)
According to the procedure described above, the collagen fraction was fractionated, and the radioactivity incorporated in the collagen fraction was measured. As a control, the same test was conducted without adding the basic protein fraction and the basic peptide fraction. The results are shown in Table 7.
【0033】[0033]
【表7】 [Table 7]
【0034】これによると、塩基性タンパク質画分及び
塩基性ペプチド画分を添加した群は、塩基性タンパク質
画分及び塩基性ペプチド画分を添加していない群に比べ
て2倍程度のコラーゲン産生促進能を示した。このこと
から、塩基性タンパク質画分および塩基性ペプチド画分
には、皮膚線維芽細胞に働きかけ、コラーゲン産生促進
作用があることが明らかとなり、美肌剤として有用であ
ることが示唆された。According to this, the group to which the basic protein fraction and the basic peptide fraction were added produced about twice as much collagen as the group to which the basic protein fraction and the basic peptide fraction were not added. Exhibited ability. From this, it was clarified that the basic protein fraction and the basic peptide fraction act on skin fibroblasts to promote collagen production, and it was suggested that they are useful as a skin beautifying agent.
【0035】[0035]
【実施例7】表8に示す組成の化粧水を常法により製造
した。Example 7 A lotion having the composition shown in Table 8 was produced by a conventional method.
【0036】[0036]
【表8】 [Table 8]
【0037】[0037]
【実施例8】表9に示す組成のクリームを常法により製
造した。Example 8 A cream having the composition shown in Table 9 was produced by a conventional method.
【0038】[0038]
【表9】 [Table 9]
【0039】[0039]
【試験例6】実施例7で得られた化粧水及び実施例8で
得られたクリームを用いて、実使用テストを行った。比
較品としては、実施例7及び8の配合で塩基性タンパク
質画分を除いたものを用いた。顔面のタルミや小ジワが
認められる乾燥肌を有する成人女子40人を、それぞれ10
人ずつ無作為に4群(A〜D群)に分け、A群の顔面には本
発明品の化粧水を、B群の顔面には比較品の化粧水を、C
群の手指には本発明品のクリームを、D群の手指には比
較品のクリームを、それぞれ1日2回通常の使用状態と同
様に塗布してもらった。その結果、本発明品の化粧水
は、比較品の化粧水に比べて、乾燥感の改善、肌荒れ改
善が顕著であり、美肌効果に優れていることが実証され
た。また、本発明品のクリームについても、比較品のク
リームに比べて、顕著な改善がみられ、肌荒れなどの自
然増悪抑制効果を有することが明らかとなった。Test Example 6 Using the lotion obtained in Example 7 and the cream obtained in Example 8, an actual use test was conducted. As a comparative product, the one obtained by removing the basic protein fraction in the formulation of Examples 7 and 8 was used. 40 adult women with dry skin with facial lumps and wrinkles
Each person is randomly divided into 4 groups (A to D groups), the lotion of the present invention is applied to the face of group A, the comparative lotion is applied to the face of group B, and C
The fingers of the group were applied with the cream of the present invention and the fingers of the group D were applied with the cream of the comparative product twice a day, respectively, in the same manner as in the normal use state. As a result, it was proved that the lotion of the product of the present invention was more excellent in dry feeling and rough skin improvement than the lotion of the comparative product, and was excellent in the skin beautifying effect. Further, the cream of the present invention also showed a remarkable improvement as compared with the cream of the comparative product, and it was revealed that it has an effect of suppressing natural aggravation such as rough skin.
【0040】[0040]
【発明の効果】本発明の美肌剤、美肌用飲食品及び化粧
水は、皮膚のコラーゲン産生を促進させる作用を有し、
皮膚老化の予防や治療に有用である。EFFECTS OF THE INVENTION The skin beautifying agent, food and drink for skin beautification and lotion of the present invention have an action of promoting collagen production in the skin,
It is useful for the prevention and treatment of skin aging.
フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 7/48 A61P 17/16 38/00 43/00 105 A61P 17/16 A61K 37/02 43/00 105 A23L 2/00 F (72)発明者 川上 浩 埼玉県川越市藤間204−5 Fターム(参考) 4B017 LC03 LK15 LK18 LK23 LP06 LP08 4B018 LB01 LB08 LE05 MD20 MD22 MD71 MD90 ME14 MF01 MF12 4C083 AA082 AC022 AC072 AC122 AC242 AC302 AC422 AC442 AC482 AD202 AD222 AD411 AD412 AD512 CC04 CC05 EE12 4C084 AA02 AA03 BA03 BA31 CA38 NA14 ZA892 ZB212 Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) A61K 7/48 A61P 17/16 38/00 43/00 105 A61P 17/16 A61K 37/02 43/00 105 A23L 2 / 00 F (72) Inventor Hiroshi Kawakami 204-5 Fujima, Kawagoe City, Saitama Prefecture F-reference (reference) 4B017 LC03 LK15 LK18 LK23 LP06 LP08 4B018 LB01 LB08 LE05 MD20 MD22 MD71 MD90 ME14 MF01 MF12 4C083 AA082 AC022 AC072 AC122 AC442 AC482 AC302 AC302 AC482 AC482 AC302 AD202 AD222 AD411 AD412 AD512 CC04 CC05 EE12 4C084 AA02 AA03 BA03 BA31 CA38 NA14 ZA892 ZB212
Claims (7)
分とする美肌剤。1. A skin beautifying agent containing a basic protein fraction derived from milk as an active ingredient.
アミノ酸組成中に塩基性アミノ酸を15重量%以上含有し
ている画分である請求項1記載の美肌剤。2. The skin beautifying agent according to claim 1, wherein the milk-derived basic protein fraction is a fraction containing 15% by weight or more of basic amino acids in its amino acid composition.
たは乳由来の原料を陽イオン交換樹脂に接触させて塩基
性タンパク質を吸着させ、この樹脂に吸着した画分を塩
濃度0.1M〜1Mの溶出液で溶出して得られる画分である請
求項1記載の美肌剤。3. The milk-derived basic protein fraction is prepared by contacting milk or a milk-derived raw material with a cation exchange resin to adsorb the basic protein, and the fraction adsorbed to the resin is added with a salt concentration of 0.1 M to The skin beautifying agent according to claim 1, which is a fraction obtained by elution with a 1 M eluate.
来の塩基性タンパク質画分をタンパク質分解酵素で分解
して得られる塩基性ペプチド画分を有効成分とする美肌
剤。4. A skin beautifying agent comprising a basic peptide fraction obtained by degrading the milk-derived basic protein fraction according to any one of claims 1 to 3 with a proteolytic enzyme as an active ingredient.
シン、キモトリプシン及びパンクレアチンよりなる群か
ら選択される少なくとも1種のタンパク質分解酵素であ
る請求項4記載の美肌剤。5. The skin-care agent according to claim 4, wherein the proteolytic enzyme is at least one proteolytic enzyme selected from the group consisting of pepsin, trypsin, chymotrypsin and pancreatin.
来の塩基性タンパク質画分または塩基性ペプチド画分を
配合した美肌用飲食品。6. A food or drink for beautiful skin containing the milk-derived basic protein fraction or basic peptide fraction according to any one of claims 1 to 5.
来の塩基性タンパク質画分または塩基性ペプチド画分を
配合した化粧料。7. A cosmetic comprising the milk-derived basic protein fraction or basic peptide fraction according to any one of claims 1 to 5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001342660A JP4291967B2 (en) | 2001-11-08 | 2001-11-08 | Skin collagen production promoter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001342660A JP4291967B2 (en) | 2001-11-08 | 2001-11-08 | Skin collagen production promoter |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003144095A true JP2003144095A (en) | 2003-05-20 |
JP4291967B2 JP4291967B2 (en) | 2009-07-08 |
Family
ID=19156477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001342660A Expired - Fee Related JP4291967B2 (en) | 2001-11-08 | 2001-11-08 | Skin collagen production promoter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4291967B2 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004098632A1 (en) * | 2003-05-07 | 2004-11-18 | Snow Brand Milk Products Co., Ltd. | Skin collagen production promoter |
JP2005119983A (en) * | 2003-10-14 | 2005-05-12 | Snow Brand Milk Prod Co Ltd | Nutritive composition |
JP2005343887A (en) * | 2004-05-28 | 2005-12-15 | Kao Corp | Elastase inhibitor |
WO2006078067A1 (en) * | 2005-01-21 | 2006-07-27 | Kurume University | Age production inhibitor, use of the same, and process for production of the same |
WO2008055310A1 (en) * | 2006-11-10 | 2008-05-15 | Murray Goulburn Co-Operative Co. Limited | Process for the preparation of angiogenin |
WO2010134384A1 (en) * | 2009-05-20 | 2010-11-25 | よつ葉乳業株式会社 | Skin function-improving composition |
WO2012043712A1 (en) * | 2010-09-30 | 2012-04-05 | 雪印メグミルク株式会社 | Skin collagen production-promoting agent |
WO2012043713A1 (en) * | 2010-09-30 | 2012-04-05 | 雪印メグミルク株式会社 | Skin collagen production-promoting agent |
WO2012043714A1 (en) * | 2010-09-30 | 2012-04-05 | 雪印メグミルク株式会社 | Skin collagen production-promoting agent |
WO2012043711A1 (en) * | 2010-09-30 | 2012-04-05 | 雪印メグミルク株式会社 | Skin collagen production-promoting agent |
WO2012043715A1 (en) * | 2010-09-30 | 2012-04-05 | 雪印メグミルク株式会社 | Skin collagen production-promoting agent |
EP2484357A1 (en) * | 2009-09-30 | 2012-08-08 | Shiseido Company, Ltd. | Oral composition for reducing skin roughness |
EP2484356A1 (en) * | 2009-09-30 | 2012-08-08 | Shiseido Company, Ltd. | Oral composition for reducing wrinkle formation |
WO2013164993A1 (en) * | 2012-05-02 | 2013-11-07 | 雪印メグミルク株式会社 | Hyaluronic acid production promoter |
EP2674163A4 (en) * | 2011-02-09 | 2015-02-11 | Megmilk Snow Brand Co Ltd | Skin collagen production promoter |
US9255123B2 (en) | 2011-03-10 | 2016-02-09 | Megmilk Snow Brand Co., Ltd. | Skin-beautifying agent |
US9789168B2 (en) | 2008-05-14 | 2017-10-17 | Agriculture Victoria Services Pty Ltd | Use of angiogenin or angiogenin agonists for treating diseases and disorders |
US9839676B2 (en) | 2012-05-10 | 2017-12-12 | Murray Goulburn Co-Operative Co., Limited | Methods of treating cancer using angiogenin or an angiogenin agonist |
-
2001
- 2001-11-08 JP JP2001342660A patent/JP4291967B2/en not_active Expired - Fee Related
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004098632A1 (en) * | 2003-05-07 | 2004-11-18 | Snow Brand Milk Products Co., Ltd. | Skin collagen production promoter |
JP4596513B2 (en) * | 2003-10-14 | 2010-12-08 | 雪印乳業株式会社 | Nutritional composition |
JP2005119983A (en) * | 2003-10-14 | 2005-05-12 | Snow Brand Milk Prod Co Ltd | Nutritive composition |
JP2005343887A (en) * | 2004-05-28 | 2005-12-15 | Kao Corp | Elastase inhibitor |
WO2006078067A1 (en) * | 2005-01-21 | 2006-07-27 | Kurume University | Age production inhibitor, use of the same, and process for production of the same |
AU2007317200A8 (en) * | 2006-11-10 | 2012-02-02 | Agriculture Victoria Services Pty Ltd. | Process for the preparation of angiogenin |
JP2010508827A (en) * | 2006-11-10 | 2010-03-25 | マリー ゴールバーン シーオー−オペレイティブ シーオー.リミテッド | Method for preparing angiogenin |
AU2007317200B8 (en) * | 2006-11-10 | 2012-02-02 | Agriculture Victoria Services Pty Ltd. | Process for the preparation of angiogenin |
US8551547B2 (en) | 2006-11-10 | 2013-10-08 | Murray Goulburn Co-Operative Co., Limited | Process for the preparation of angiogenin |
WO2008055310A1 (en) * | 2006-11-10 | 2008-05-15 | Murray Goulburn Co-Operative Co. Limited | Process for the preparation of angiogenin |
US10456453B2 (en) | 2008-05-14 | 2019-10-29 | Agriculture Victoria Services Pty Ltd | Use of angiogenin or angiogenin agonists for treating diseases and disorders |
US9789168B2 (en) | 2008-05-14 | 2017-10-17 | Agriculture Victoria Services Pty Ltd | Use of angiogenin or angiogenin agonists for treating diseases and disorders |
WO2010134384A1 (en) * | 2009-05-20 | 2010-11-25 | よつ葉乳業株式会社 | Skin function-improving composition |
EP2484357A4 (en) * | 2009-09-30 | 2013-11-20 | Shiseido Co Ltd | Oral composition for reducing skin roughness |
EP2484357A1 (en) * | 2009-09-30 | 2012-08-08 | Shiseido Company, Ltd. | Oral composition for reducing skin roughness |
EP2484356A4 (en) * | 2009-09-30 | 2013-12-04 | Shiseido Co Ltd | Oral composition for reducing wrinkle formation |
EP2484356A1 (en) * | 2009-09-30 | 2012-08-08 | Shiseido Company, Ltd. | Oral composition for reducing wrinkle formation |
WO2012043714A1 (en) * | 2010-09-30 | 2012-04-05 | 雪印メグミルク株式会社 | Skin collagen production-promoting agent |
JP2012077017A (en) * | 2010-09-30 | 2012-04-19 | Snow Brand Milk Products Co Ltd | Skin collagen production-promoting agent |
JP2012077015A (en) * | 2010-09-30 | 2012-04-19 | Snow Brand Milk Products Co Ltd | Skin collagen production promoter |
JP2012077019A (en) * | 2010-09-30 | 2012-04-19 | Snow Brand Milk Products Co Ltd | Skin collagen production-promoting agent |
CN103269707A (en) * | 2010-09-30 | 2013-08-28 | 雪印惠乳业株式会社 | Skin collagen production-romoting agent |
WO2012043711A1 (en) * | 2010-09-30 | 2012-04-05 | 雪印メグミルク株式会社 | Skin collagen production-promoting agent |
WO2012043712A1 (en) * | 2010-09-30 | 2012-04-05 | 雪印メグミルク株式会社 | Skin collagen production-promoting agent |
WO2012043715A1 (en) * | 2010-09-30 | 2012-04-05 | 雪印メグミルク株式会社 | Skin collagen production-promoting agent |
WO2012043713A1 (en) * | 2010-09-30 | 2012-04-05 | 雪印メグミルク株式会社 | Skin collagen production-promoting agent |
JP2012077018A (en) * | 2010-09-30 | 2012-04-19 | Snow Brand Milk Products Co Ltd | Skin collagen production-promoting agent |
EP2674163A4 (en) * | 2011-02-09 | 2015-02-11 | Megmilk Snow Brand Co Ltd | Skin collagen production promoter |
US9763868B2 (en) | 2011-02-09 | 2017-09-19 | Megmilk Snow Brand Co., Ltd. | Skin collagen production-promoting agent |
US9255123B2 (en) | 2011-03-10 | 2016-02-09 | Megmilk Snow Brand Co., Ltd. | Skin-beautifying agent |
JP2013234129A (en) * | 2012-05-02 | 2013-11-21 | Snow Brand Milk Products Co Ltd | Hyaluronic acid production promotor |
TWI602581B (en) * | 2012-05-02 | 2017-10-21 | 雪印惠乳業股份有限公司 | Hyaluronic acid production promoter |
WO2013164993A1 (en) * | 2012-05-02 | 2013-11-07 | 雪印メグミルク株式会社 | Hyaluronic acid production promoter |
US9839676B2 (en) | 2012-05-10 | 2017-12-12 | Murray Goulburn Co-Operative Co., Limited | Methods of treating cancer using angiogenin or an angiogenin agonist |
Also Published As
Publication number | Publication date |
---|---|
JP4291967B2 (en) | 2009-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4291967B2 (en) | Skin collagen production promoter | |
US20100035819A1 (en) | Method of promoting skin collagen production | |
JP6259209B2 (en) | Collagen production promoter | |
JP4023648B2 (en) | Skin metabolism promoter and functional food | |
JP5890100B2 (en) | Skin collagen production promoter | |
KR101789355B1 (en) | Skin collagen production-promoting agent | |
JP4698935B2 (en) | Skin collagen production promoter | |
JP6877924B2 (en) | Epidermal cell-cell function enhancer | |
JP5955499B2 (en) | Skin collagen production promoter | |
JPH06157233A (en) | Odorless or low-odoriferous component from fish-and-shellfish peptide, its production and external or internal preparation containing the same | |
JP5993308B2 (en) | Sensory improver | |
JP5955630B2 (en) | Hyaluronic acid production promoter | |
JP5783484B2 (en) | Skin collagen production promoter | |
JP4698934B2 (en) | Skin collagen production promoter | |
JP2004331564A (en) | Skin collagen production enhancer | |
JP2012077015A (en) | Skin collagen production promoter | |
JP2012077017A (en) | Skin collagen production-promoting agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040914 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20051026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060110 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20060110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060111 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060525 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060530 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20060908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080604 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090406 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4291967 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130410 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130410 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140410 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |